Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06034652 · ClinicalTrials.gov registry record
T-GENVIH-003 LTFU (Long Term Follow Up) Study
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- 8
- Enrollment target
NCT06034652: Completed study, sponsored by Integra LifeSciences Corporation.
NCT06034652 is a clinical trial that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06034652 has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The T-GENVIH-003 study will collect additional, longer term performance data of Gentrix® Surgical Matrix used for reinforcement of ventral hernia repairs from a subset population (i.e., the twenty-one minimally invasive surgical approach cases) from the prior T-GENVIH-002 study.
Primary Outcome
1\. Incidence of clinically confirmed recurrence of the primary hernia to date, including not previously reported in T-GENVIH-002 study.
Interventions
- DEVICE Integra® Gentrix® Surgical Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2024-01-19 |
What the finished NCT06034652 record still lists
NCT06034652 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Integra® Gentrix® Surgical Matrix is the first listed.
NCT06034652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06034652 about?
NCT06034652 is a clinical study titled "T-GENVIH-003 LTFU (Long Term Follow Up) Study". The T-GENVIH-003 study will collect additional, longer term performance data of Gentrix® Surgical Matrix used for reinforcement of ventral hernia repairs from a subset population (i.e., the twenty-one minimally invasive surgical approach cases) from the prior T-GENVIH-002 study.
What is the current status of trial NCT06034652?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2023-09-12. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT06034652?
The interventions under investigation include: Integra® Gentrix® Surgical Matrix (DEVICE).
Who is sponsoring clinical trial NCT06034652?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI